TECH - Bio-Techne Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
205.84
-4.47 (-2.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close210.31
Open209.97
Bid0.00 x 800
Ask0.00 x 800
Day's Range205.62 - 209.97
52 Week Range132.75 - 216.47
Volume107,932
Avg. Volume152,660
Market Cap7.796B
Beta (3Y Monthly)1.55
PE Ratio (TTM)65.68
EPS (TTM)3.13
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & Yield1.28 (0.65%)
Ex-Dividend Date2019-05-09
1y Target Est210.71
Trade prices are not sourced from all markets
  • Here’s What Hedge Funds Think About Bio-Techne Corporation (TECH)
    Insider Monkey6 days ago

    Here’s What Hedge Funds Think About Bio-Techne Corporation (TECH)

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 8 months is one of those periods, as the Russell 2000 […]

  • GuruFocus.com7 days ago

    Royce Funds Commentary: Lauren Romeo on 4 Quality Cyclicals

    By Portfolio Manager and Principal Lauren Romeo, CFA

  • PR Newswire8 days ago

    FDA Grants Breakthrough Device Designation To Bio-Techne's ExoDx™ Prostate IntelliScore™ (EPI) Test

    MINNEAPOLIS , June 17, 2019 /PRNewswire/ -- Bio-Techne today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its ExoDx Prostate IntelliScore (EPI) ...

  • PR Newswire12 days ago

    Bio-Techne Receives Approval To Offer The ExoDx™ Prostate Intelliscore™ (EPI) Test In New York State

    MINNEAPOLIS, June 13, 2019 /PRNewswire/ -- Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate IntelliScore (EPI) test in New York, providing a valuable tool to help Urologists rule out unnecessary prostate biopsies. The EPI test was launched in the U.S. in 2017. With this approval, the EPI test is now available to Urologists in New York State.

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Bio-Techne Corp.

    Bio-Techne Corp NASDAQ/NGS:TECHView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for TECH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting TECH. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $894 million over the last one-month into ETFs that hold TECH are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • If You Like EPS Growth Then Check Out Bio-Techne (NASDAQ:TECH) Before It's Too Late
    Simply Wall St.19 days ago

    If You Like EPS Growth Then Check Out Bio-Techne (NASDAQ:TECH) Before It's Too Late

    It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

  • The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
    Zacks20 days ago

    The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

    The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

  • Myriad Genetics Announces Study Results Of myRisk Cancer Test
    Zacks20 days ago

    Myriad Genetics Announces Study Results Of myRisk Cancer Test

    The results of the studies will provide a major breakthrough for Myriad Genetics (MYGN) in the field of breast cancer diagnosis and treatment.

  • PR Newswire21 days ago

    Bio-Techne To Acquire B-MoGen Biotechnologies Inc.

    MINNEAPOLIS, June 4, 2019 /PRNewswire/ -- Bio-Techne Corporation (TECH) announced today it has reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc. The transaction has been completed and is being financed through available cash on hand. "We are very pleased to include the B-MoGen technology in Bio-Techne's expanding portfolio of products that serve the rapidly growing cell and gene therapy markets," commented Charles R. Kummeth, President and Chief Executive Officer of Bio-Techne.  "B-MoGen's technologies solve the most complex gene editing problems with proprietary, cutting edge gene editing and delivery tools, enabling and accelerating growth in immunotherapy treatments.

  • 5 Biotech Stocks to Buy Right Now
    Zacks21 days ago

    5 Biotech Stocks to Buy Right Now

    here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank 2 (Buy) or better.

  • Bio-Techne To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
    PR Newswire22 days ago

    Bio-Techne To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

    MINNEAPOLIS , June 3, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Goldman Sachs 40 th Annual ...

  • PR Newswire28 days ago

    Bio-Techne's New Exosome-Based Liquid Biopsies Helping To Advance Personalized Care In Lung Cancer Diagnostics

    MINNEAPOLIS, May 28, 2019 /PRNewswire/ -- Bio-Techne today announced the publication of a recent validation study demonstrating that the proprietary exosome-based liquid biopsy tests from Bio-Techne's Exosome Diagnostics brand may be used to assess the mutational status of the Epidermal Growth Factor Receptor (EGFR) gene in patients with non-small cell lung cancer (NSCLC). The data from this study will be available to discuss at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 31 to June 4 in Chicago, IL. NSCLC is the most common type of lung cancer.

  • CBM vs. TECH: Which Stock Is the Better Value Option?
    Zackslast month

    CBM vs. TECH: Which Stock Is the Better Value Option?

    CBM vs. TECH: Which Stock Is the Better Value Option?

  • Bio-Techne To Present At The Jefferies 2019 Global Healthcare Conference
    PR Newswirelast month

    Bio-Techne To Present At The Jefferies 2019 Global Healthcare Conference

    MINNEAPOLIS , May 21, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare ...

  • Does Bio-Techne Corporation's (NASDAQ:TECH) Past Performance Indicate A Stronger Future?
    Simply Wall St.last month

    Does Bio-Techne Corporation's (NASDAQ:TECH) Past Performance Indicate A Stronger Future?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Bio-Techne To Present At The UBS Global Healthcare Conference
    PR Newswirelast month

    Bio-Techne To Present At The UBS Global Healthcare Conference

    MINNEAPOLIS , May 14, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the UBS Global Healthcare Conference ...

  • Roche expands partnership with Bio-Techne to offer drug discovery researchers new chromogenic detection options for mRNA ISH tissue analysis
    PR Newswire2 months ago

    Roche expands partnership with Bio-Techne to offer drug discovery researchers new chromogenic detection options for mRNA ISH tissue analysis

    New Roche detection kits, combined with Bio-Techne's ACD RNAscope® reagent kits, increase singleplex and multiplex testing capabilities on automated platform INDIANAPOLIS , May 6, 2019 /PRNewswire/ -- ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of TECH earnings conference call or presentation 30-Apr-19 1:00pm GMT

    Q3 2019 Bio-Techne Corp Earnings Call

  • Bio-Techne To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference
    PR Newswire2 months ago

    Bio-Techne To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference

    MINNEAPOLIS , May 2, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Jim Hippel , Chief Financial Officer will present at the Bank of America Merrill Lynch 2019 Health Care ...

  • Bio-Techne Corp (TECH) Q3 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Bio-Techne Corp (TECH) Q3 2019 Earnings Call Transcript

    TECH earnings call for the period ending March 31, 2019.

  • PR Newswire2 months ago

    Bio-Techne Releases Third Quarter Fiscal 2019 Results

    MINNEAPOLIS , April 30, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the third quarter ended March 31, 2019 . Third Quarter FY2019 Snapshot Third quarter ...

  • PR Newswire2 months ago

    Bio-Techne Declares Dividend

    MINNEAPOLIS , April 30, 2019 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, ...